Metabolite profiling of fecal water extracts from human colorectal cancer

Colorectal cancer is the second leading cause of cancer death in developed countries. There is a need for better preventive strategies to improve the outcome of this disease. The increasing availability of high‐throughput methodologies opens up new possibilities for screening new markers. The application of NMR metabolic profiling to fecal water extracts has interesting potential as a diagnostic tool for detecting colorectal cancer. We obtained NMR metabolic profiles of fecal water extracts from patients with colorectal cancer and healthy individuals, to characterize possible differences between them and to identify potential diagnostic markers. Our results show that metabolic profiling of fecal water extracts is a cheap, reproducible and effective method for detecting colorectal cancer markers and therefore complements other stool‐screening methods. A low concentration of short‐chain fatty acids, such as acetate and butyrate, previously associated with the development of colorectal cancer, appears to be the most effective marker. Concentrations of proline and cysteine, which are major components of most colonic epithelium mucus glycoproteins, also display significant changes in samples from colorectal cancer. Differentiation between fecal water extracts from controls and patients with colorectal cancer by NMR spectroscopy combined with chemometric techniques opens up new possibilities for developing new, efficient, high‐throughput screening protocols. Copyright © 2008 John Wiley & Sons, Ltd.

[1]  D. Evans,et al.  Molecular stool screening for colorectal cancer , 2004, The British journal of surgery.

[2]  J. Lovegrove,et al.  The gut microbiota and lipid metabolism: implications for human health and coronary heart disease. , 2006, Current medicinal chemistry.

[3]  J. Lindon,et al.  Metabonomics: a platform for studying drug toxicity and gene function , 2002, Nature Reviews Drug Discovery.

[4]  J. Jass,et al.  Altered mucin expression in the gastrointestinal tract: a review , 2001, Journal of cellular and molecular medicine.

[5]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[6]  Elaine Holmes,et al.  Metabonomics in pharmaceutical R & D , 2007, The FEBS journal.

[7]  J. Nicholson,et al.  Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. , 2003, The Analyst.

[8]  A. Evdokiou,et al.  Involvement of p21(Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate. , 2000, Carcinogenesis.

[9]  D. Ahlquist,et al.  Stool markers for colorectal cancer screening: future considerations. , 1996, Digestive diseases.

[10]  L. Martí-Bonmatí,et al.  Metabolite identification in human liver needle biopsies by high‐resolution magic angle spinning 1H NMR spectroscopy , 2006, NMR in biomedicine.

[11]  S. Lewis,et al.  Stool form scale as a useful guide to intestinal transit time. , 1997, Scandinavian journal of gastroenterology.

[12]  H. Frederiksen,et al.  Dietary proanthocyanidins: occurrence, dietary intake, bioavailability, and protection against cardiovascular disease. , 2005, Molecular nutrition & food research.

[13]  Kirill Veselkov,et al.  Species variation in the fecal metabolome gives insight into differential gastrointestinal function. , 2008, Journal of proteome research.

[14]  K. Kinzler,et al.  Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. , 1992, Science.

[15]  J. Lupton,et al.  Modulation of colonic epithelial cell proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats. , 1992, Cancer research.

[16]  D. Palli,et al.  Fecal Levels of Short-Chain Fatty Acids and Bile Acids as Determinants of Colonic Mucosal Cell Proliferation in Humans , 2002, Nutrition and cancer.

[17]  R. Dubrow,et al.  Fecal protein markers of colorectal cancer. , 1992, The American journal of gastroenterology.

[18]  C. Wagener,et al.  Detection of K‐ras mutations in stools of patients with colorectal cancer by mutant‐enriched PCR , 1996, International journal of cancer.

[19]  Constance M. Johnson,et al.  Screening for Colorectal Cancer: A Comparison of 3 Fecal Occult Blood Tests , 1997 .

[20]  Henrik Antti,et al.  Application of orthogonal signal correction to minimise the effects of physical and biological variation in high resolution 1H NMR spectra of biofluids. , 2002, The Analyst.

[21]  S. Schreiber,et al.  Fiber-derived butyrate and the prevention of colon cancer. , 1997, Chemistry & biology.

[22]  M. Tanner,et al.  Metabonomic investigations in mice infected with Schistosoma mansoni: an approach for biomarker identification. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Ochiai,et al.  Frequent detection of K-ras mutation in stool samples of colorectal carcinoma patients after improved DNA extraction: comparison with tissue samples. , 2002, International journal of oncology.

[24]  A. Rebecchi,et al.  Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. , 1996, Gastroenterology.

[25]  Mark R. Viant,et al.  Improved classification accuracy in 1- and 2-dimensional NMR metabolomics data using the variance stabilising generalised logarithm transformation , 2007, BMC Bioinformatics.

[26]  B. Evers,et al.  Stimulation of the intestinal Cdx2 homeobox gene by butyrate in colon cancer cells , 2002, Gut.

[27]  L. Martí-Bonmatí,et al.  1H and 13C HR‐MAS spectroscopy of intact biopsy samples ex vivo and in vivo 1H MRS study of human high grade gliomas , 2004, NMR in biomedicine.

[28]  T. Walle.  Absorption and metabolism of flavonoids. , 2004, Free radical biology & medicine.

[29]  C. Paraskeva,et al.  The short-chain fatty acid butyrate induces apoptosis in colorectal tumour cell lines. , 1995, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[30]  R. Bresalier,et al.  Mucins and mucin binding proteins in colorectal cancer , 2004, Cancer and Metastasis Reviews.

[31]  R. Dubrow,et al.  Fecal lysozyme: an unreliable marker for colorectal cancer. , 1992, The American journal of gastroenterology.

[32]  D. Ahlquist,et al.  Stool screening for colorectal cancer: molecular approaches. , 2005, Gastroenterology.

[33]  S. Gendler,et al.  Epithelial mucin genes. , 1995, Annual review of physiology.

[34]  P. Pouillart,et al.  Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies. , 1998, Life sciences.

[35]  T. Kanematsu,et al.  Mutations of the p53 gene in the stool of patients with resectable colorectal cancer , 1996, Cancer.

[36]  L. Påhlman,et al.  Screening for colorectal cancer , 1997, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[37]  S. Bingham,et al.  Mechanisms and experimental and epidemiological evidence relating dietary fibre (non-starch polysaccharides) and starch to protection against large bowel cancer , 1990, Proceedings of the Nutrition Society.

[38]  L. Garfinkel,et al.  U.S. cancer incidence, mortality and survival: 1973-1996. , 1999, Statistical bulletin.

[39]  P. Vos,et al.  Standardization for transcriptomic molecular markers to screen human colon cancer. , 2007, Cancer genomics & proteomics.

[40]  I. Wilson,et al.  Gut microorganisms, mammalian metabolism and personalized health care , 2005, Nature Reviews Microbiology.

[41]  L M Schuman,et al.  Sensitivity, specificity, and positive predictivity of the Hemoccult test in screening for colorectal cancers. The University of Minnesota's Colon Cancer Control Study. , 1989, Gastroenterology.

[42]  Yonggoo Kim,et al.  Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen. , 2003, Annals of clinical and laboratory science.

[43]  I. Wilson,et al.  Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. , 2007, Journal of proteome research.

[44]  S. Batra,et al.  Structural organization and classification of the human mucin genes. , 2001, Frontiers in bioscience : a journal and virtual library.

[45]  L. Ferguson,et al.  Dietary fibres as "prebiotics": implications for colorectal cancer. , 2005, Molecular nutrition & food research.

[46]  G. Rechkemmer,et al.  Potential of short chain fatty acids to modulate the induction of DNA damage and changes in the intracellular calcium concentration by oxidative stress in isolated rat distal colon cells. , 1999, Carcinogenesis.

[47]  C. Probert,et al.  Mucins in the gastrointestinal tract in health and disease. , 2001, Frontiers in bioscience : a journal and virtual library.

[48]  E. Vaughan,et al.  1H NMR metabolite profiling of feces as a tool to assess the impact of nutrition on the human microbiome , 2008, NMR in biomedicine.

[49]  D. Monleón,et al.  Determination of metabolite concentrations in human brain tumour biopsy samples using HR‐MAS and ERETIC measurements , 2009, NMR in biomedicine.

[50]  W. Bodmer,et al.  Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. , 1995, Gut.

[51]  D. Monleón,et al.  Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling. , 2008, Journal of proteome research.

[52]  I. Hirata,et al.  Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases. , 2007, World journal of gastroenterology.